We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Zogenix closes $36mm first tranche of Series B; total is $71mm
09 Dec 2009
Executive Summary
Just over a year after withdrawing its initial public offering, Zogenix (pain management drug candidates) has raised $36mm in the first tranche of its Series B preferred stock financing from lead returning backers Clarus Ventures and Domain Associates. First-time investor Oxford Finance also participated along with all existing shareholders including Scale Venture Partners, Thomas, McNerney & Partners, and Abingworth Management. The company's board has the right to call a second tranche of $15mm between December 2009 and February 2010. (According to the Form D, Zogenix could raise a total of $60mm through this financing.) Under a US co-promote deal signed last month with Astellas Pharma US, Zogenix plans to launch its migraine product Sumavel DosePro (sumatriptan) at the start of next year, and will specifically use the Series B funds to build up inventory of the drug and set up a 105-person sales force.
Deal Industry
Medical Devices
Pharmaceuticals
Pharmaceuticals
Drug Delivery
Specialty Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?